NASDAQ · Financial Statements

DiaMedica Therapeutics Inc. (DMAC) Financial Statements

$8.72 NASDAQ: DMAC Market Cap $470.23M

DiaMedica Therapeutics Inc. most recently reported annual revenue of $0, a net loss of $33.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

DiaMedica Therapeutics Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $33.0M.

Income Statement — 10 Years (USD millions)

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	$0	$0	$1.0M	$0	$0	$0	$0	$0	$0	$0
Operating Expenses	$2.0M	$5.0M	$7.0M	$12.0M	$13.0M	$14.0M	$14.0M	$21.0M	$27.0M	$34.0M
Operating Profit	$-2.0M	$-5.0M	$-7.0M	$-12.0M	$-13.0M	$-14.0M	$-14.0M	$-21.0M	$-27.0M	$-34.0M
Operating Margin	0.0%	0.0%	-1352.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other Income	$0	$0	$1.0M	$1.0M	$0	$0	$0	$2.0M	$2.0M	$2.0M
Interest	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Depreciation	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Profit Before Tax	$-2.0M	$-4.0M	$-6.0M	$-11.0M	$-12.0M	$-14.0M	$-14.0M	$-19.0M	$-24.0M	$-33.0M
Tax	$-1.0M	$210,000	$-1.4M	$-290,000	$-220,000	$-210,000	$-210,000	$-220,000	$-120,000	$-90,000
Net Profit	$-2.0M	$-4.0M	$-6.0M	$-11.0M	$-12.0M	$-14.0M	$-14.0M	$-19.0M	$-24.0M	$-33.0M
EPS	$-0.47	$-0.72	$-0.74	$-0.89	$-0.78	$-0.65	$-0.52	$-0.60	$-0.60	$-0.70
Dividend Payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

Metric	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Operating Expenses	$5.0M	$6.0M	$6.0M	$6.0M	$7.0M	$8.0M	$8.0M	$8.0M	$9.0M	$9.0M	$10.0M	$10.0M
Operating Profit	$-5.0M	$-6.0M	$-6.0M	$-6.0M	$-7.0M	$-8.0M	$-8.0M	$-8.0M	$-9.0M	$-9.0M	$-10.0M	$-10.0M
Operating Margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Profit Before Tax	$-4.0M	$-5.0M	$-5.0M	$-5.0M	$-6.0M	$-8.0M	$-8.0M	$-8.0M	$-9.0M	$-9.0M	$-10.0M	$-10.0M
Tax	$-160,000	$-430,000	$-140,000	$-140,000	$-110,000	$-110,000	$-80,000	$-80,000	$-70,000	$-110,000	$70,000	$-70,000
Net Profit	$-4.0M	$-5.0M	$-5.0M	$-5.0M	$-6.0M	$-8.0M	$-8.0M	$-8.0M	$-9.0M	$-9.0M	$-10.0M	$-10.0M
EPS	$-0.12	$-0.14	$-0.14	$-0.13	$-0.15	$-0.18	$-0.18	$-0.18	$-0.17	$-0.17	$-0.19	$-0.19

Over the 10 years reported for DiaMedica Therapeutics Inc., cash stood at $16.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 12.20 times.

Balance Sheet — 10 Years (USD millions)

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	$2.0M	$2.0M	$18.0M	$9.0M	$28.0M	$46.0M	$34.0M	$54.0M	$46.0M	$61.0M
Current Assets	$2.0M	$1.0M	$18.0M	$9.0M	$28.0M	$45.0M	$34.0M	$54.0M	$45.0M	$61.0M
Cash	$2.0M	$1.0M	$17.0M	$4.0M	$7.0M	$5.0M	$5.0M	$5.0M	$3.0M	$16.0M
Inventory	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Receivables	$0	$0	$1.0M	$1.0M	$0	$0	$0	$0	$0	$0
Fixed Assets	$0	$0	$0	$0	$0	$0	$1.0M	$0	$0	$0
Capital Work in Progress	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Investments	$0	$0	$0	$4.0M	$20.0M	$40.0M	$29.0M	$48.0M	$41.0M	$44.0M
Other Assets	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.0M	$1.0M	$1.0M	$1.0M	$2.0M	$2.0M	$3.0M	$3.0M	$6.0M	$5.0M
Current Liabilities	$1.0M	$1.0M	$1.0M	$1.0M	$2.0M	$2.0M	$2.0M	$3.0M	$5.0M	$5.0M
Borrowings	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Other Liabilities	$0	$1.0M	$1.0M	$1.0M	$2.0M	$1.0M	$2.0M	$3.0M	$5.0M	$5.0M
Equity	$41.0M	$0	$0	$0	$0	$0	$0	$0	$0	$0
Reserves	$1.0M	$1.0M	$17.0M	$8.0M	$26.0M	$44.0M	$32.0M	$51.0M	$41.0M	$56.0M

For DiaMedica Therapeutics Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $29.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating Cash Flow	$-3.0M	$-4.0M	$-6.0M	$-9.0M	$-9.0M	$-12.0M	$-12.0M	$-19.0M	$-22.0M	$-29.0M
Investing Cash Flow	$0	$0	$0	$-4.0M	$-16.0M	$-21.0M	$11.0M	$-18.0M	$9.0M	$-2.0M
Financing Cash Flow	$0	$1.0M	$1.0M	$0	$0	$0	$0	$0	$0	$0
Net Cash Flow	$2.0M	$0	$15.0M	$-13.0M	$4.0M	$-3.0M	$0	$0	$-2.0M	$13.0M
Free Cash Flow	$-3.0M	$-4.0M	$-6.0M	$-9.0M	$-9.0M	$-12.0M	$-12.0M	$-19.0M	$-22.0M	$-29.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	2.66
EV / EBITDA	-11.82
FCF Yield	-7.13%
Quick Ratio	6.72
Interest Coverage	—
Return 1Y	32.43%
Return 3Y	96.54%
Return 5Y	98.96%

DiaMedica Therapeutics Inc. (DMAC) financials — frequently asked questions

What is DiaMedica Therapeutics Inc.'s annual revenue?

DiaMedica Therapeutics Inc. (DMAC) reported annual revenue of $0 in its most recent fiscal year.

What is DiaMedica Therapeutics Inc.'s net profit?

DiaMedica Therapeutics Inc. (DMAC) reported a net loss of $33.0M in its most recent fiscal year.

What is DMAC EV/EBITDA?

DiaMedica Therapeutics Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -11.82. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

DMAC Overview DMAC Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.